Pulmonx (4NI) Price & Analysis

0 Followers

4NI Stock Chart & Stats

€1.58

-€0.05(-0.78%)

At close: Jan 08 4:00 PM EST

€1.58

-€0.05(-0.78%)

Day’s Range― - ―

52-Week Range€0.99 - €3.18

Previous CloseN/A

Volume0.00

Average Volume (3M)276.00

Market Cap

€46.98M

Enterprise Value€48.51

Total Cash (Recent Filing)€61.57M

Total Debt (Recent Filing)€56.29M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Jul 29, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.30

Shares Outstanding42,237,200

10 Day Avg. Volume200

30 Day Avg. Volume276

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)1.66

Price to Sales (P/S)0.99

P/FCF Ratio-2.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.05

Price Target Upside93.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-1

Revenue Forecast (FY)€79.79M

Bulls Say, Bears Say

Bulls Say

High Gross MarginsPulmonx’s mid-70% gross margins reflect strong unit economics typical of implantable medical devices. Durable high margins provide structural profit potential as volumes recover, enabling faster operating leverage and more efficient reinvestment into sales, R&D, and clinical programs when revenue growth resumes.

Clinical Pipeline Expands TAMProgress in the CONVERT II trial and the potential AeriSeal approval represent a structural growth catalyst that can broaden eligible patient cohorts and diversify revenue beyond the Zephyr valve. A successful approval would increase long-term addressable market and reduce single-product concentration risk.

Extended Liquidity And Lower BurnThe new five-year facility plus a >10% cost reduction materially extend runway and lower refinancing urgency. Combined with current cash and reduced projected burn, this provides durable financial flexibility to execute commercialization and clinical plans without immediate financing stress, reducing near-term solvency risk.

Bears Say

Revenue DeclineA sustained pullback in revenue undermines scale economics and delays operating leverage for a device company that depends on procedure volume. If demand recovery lags, fixed R&D and SG&A will continue to pressure margins and cash flow, making growth and profitability outcomes execution-dependent.

Negative Cash Flow ProfilePersistent negative operating and free cash flow means the business cannot internally fund growth or clinical programs, forcing reliance on debt or equity. That dependence increases dilution or leverage risk and limits strategic optionality until the company demonstrably reaches sustained positive cash generation.

Execution And Access RiskRecovery is contingent on new sales hires hitting productivity and regulatory timing in China; both carry multi-month uncertainty. Delays in rep productivity or registration can defer procedure adoption and revenue, making medium-term results highly execution-sensitive and increasing the risk of missed guidance.

Pulmonx News

Pulmonx Shareholders Back Board, Auditor and Pay Program

Pulmonx ( ($LUNG) ) has provided an update. On June 4, 2026, Pulmonx Corporation held its 2026 Annual...

2M ago

LUNG

Pulmonx Earnings Call: Margin Gains Amid Growth Pause

Pulmonx Corporation (($LUNG)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

LUNG

Pulmonx reports Q1 EPS (33c), consensus (33c)

Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and...

3M ago

LUNG

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the...

3M ago

LUNG

Pulmonx Faces Legal, Regulatory and Financial Risks From Off‑Label Use of Its Products

Pulmonx Corporation (LUNG) has disclosed a new risk, in the Corporate Activity and Growth category. Pulmonx Corporation faces...

4M ago

LUNG

Pulmonx Earnings Call: Cost Discipline Amid Growth Pause

Pulmonx Corporation (($LUNG)) has held its Q4 earnings call. Read on for the main highlights of the call....

5M ago

LUNG

Pulmonx price target lowered to $5 from $6 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Pulmonx (LUNG) to $5 from $6 and keeps...

5M ago

LUNG

Pulmonx Secures New Term Loan and Issues Warrants

An update from Pulmonx ( ($LUNG) ) is now available. On March 2, 2026, Pulmonx Corporation entered into...

5M ago

LUNG

Pulmonx reports Q4 EPS (25c), consensus (38c)

Reports Q4 revenue $22.6M, consensus $21.73M. “While our recent performance reflects a period of transition, we see a...

5M ago

LUNG

Pulmonx sees FY26 revenue $90M-$92M, consensus $94.23M

The company said, “Pulmonx (LUNG) expects revenue for the full year 2026 to be in the range of...

5M ago

LUNG

Pulmonx Corporation (LUNG) Q4 Earnings Cheat Sheet

Pulmonx Corporation (LUNG) is scheduled to report 4th quarter earnings on 03/04/2026, after the market closes. Regarding Q4...

5M ago

LUNG

Pulmonx Corporation’s Earnings Call: Mixed Results and Strategic Focus

Pulmonx Corporation (($LUNG)) has held its Q3 earnings call. Read on for the main highlights of the call....

8M ago

LUNG

Pulmonx: Buy Rating Affirmed Amid Leadership Return and Promising Growth Prospects

Canaccord Genuity analyst John Young CFA maintained a Buy rating on Pulmonx yesterday and set a price target...

8M ago

LUNG

Pulmonx Corporation Reports Q3 2025 Financial Results

Pulmonx Corporation ( ($LUNG) ) has released its Q3 earnings. Here is a breakdown of the information Pulmonx...

8M ago

LUNG

4NI FAQ

What was Pulmonx Corporation’s price range in the past 12 months?

Pulmonx Corporation lowest stock price was €0.99 and its highest was €3.18 in the past 12 months.

What is Pulmonx Corporation’s market cap?

Pulmonx Corporation’s market cap is €46.98M.

When is Pulmonx Corporation’s upcoming earnings report date?

Pulmonx Corporation’s upcoming earnings report date is Jul 29, 2026 which is in 6 days.

How were Pulmonx Corporation’s earnings last quarter?

Pulmonx Corporation released its earnings results on Apr 29, 2026. The company reported -€0.289 earnings per share for the quarter, missing the consensus estimate of -€0.286 by -€0.003.

Is Pulmonx Corporation overvalued?

According to Wall Street analysts Pulmonx Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pulmonx Corporation pay dividends?

Pulmonx Corporation does not currently pay dividends.

What is Pulmonx Corporation’s EPS estimate?

Pulmonx Corporation’s EPS estimate is -0.25.

How many shares outstanding does Pulmonx Corporation have?

Pulmonx Corporation has 42,237,200 shares outstanding.

What happened to Pulmonx Corporation’s price movement after its last earnings report?

Pulmonx Corporation reported an EPS of -€0.289 in its last earnings report, missing expectations of -€0.286. Following the earnings report the stock price went down -0.962%.

Which hedge fund is a major shareholder of Pulmonx Corporation?

Currently, no hedge funds are holding shares in DE:4NI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pulmonx Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-20.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pulmonx Corporation

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Pulmonx (4NI) Earnings & Revenues

Historic Earnings Reports

4NI Stock 12 Month Forecast

Average Price Target

€3.05

▲(93.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","1.25":"€1.25","2.5":"€2.5","3.75":"€3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.36115225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.052806575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.180576125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.378550173076923,1.627100346153846,1.8756505192307693,2.124200692307692,2.3727508653846154,2.6213010384615387,2.8698512115384616,3.1184013846153844,3.3669515576923077,3.615501730769231,3.864051903846154,4.112602076923077,{"y":4.36115225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.277908198076923,1.425816396153846,1.5737245942307692,1.7216327923076922,1.8695409903846152,2.0174491884615384,2.1653573865384614,2.3132655846153845,2.4611737826923075,2.6090819807692305,2.756990178846154,2.904898376923077,{"y":3.052806575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.2108135480769229,1.291627096153846,1.372440644230769,1.4532541923076923,1.5340677403846152,1.6148812884615382,1.6956948365384614,1.7765083846153846,1.8573219326923076,1.9381354807692306,2.018949028846154,2.0997625769230766,{"y":2.180576125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.839,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >